marie hudson,hugues richard,louise pilote bmj 2005;330:1370
DESCRIPTION
Kaplan-Meier analysis of time to recurrent congestive heart failure or death in patients prescribed celecoxib, rofecoxib, or non-steroidal anti-inflammatory drugs. Marie Hudson,Hugues Richard,Louise Pilote BMJ 2005;330:1370. - PowerPoint PPT PresentationTRANSCRIPT
Kaplan-Meier analysis of time to recurrent congestive heart failure or death in patients
prescribed celecoxib, rofecoxib, or non-steroidal anti-inflammatory drugs
Marie Hudson,Hugues Richard,Louise Pilote BMJ 2005;330:1370
Kaplan-Meier analysis of time to death in patients prescribed celecoxib, rofecoxib,or
non-steroidal anti-inflammatory drugs
Marie Hudson,Hugues Richard,Louise Pilote BMJ 2005;330:1370
Baseline characteristics of patients with congestive
heart failure prescribed celecoxib,rofecoxib,or
non-steroidal anti-inflammatory drugs (NSAIDs)
Marie Hudson,Hugues Richard,Louise Pilote BMJ 2005;330:1370
Prescribing characteristics for patients given celecoxib,rofecoxib,or non-steroidal
anti-inflammatory drugs (NSAIDs)
Marie Hudson,Hugues Richard,Louise Pilote BMJ 2005;330:1370
Kaplan-Meier analysis of time to recurrent congestive heart failure in patients
prescribed celecoxib, rofecoxib, or non-steroidal anti-inflammatory drugs
Marie Hudson,Hugues Richard,Louise Pilote BMJ 2005;330:1370
Unadjusted rates of study events in patients
with congestive heart failure who were prescribed celecoxib,rofecoxib,or non-
steroidal anti-inflammatory drugs (NSAIDs)
Marie Hudson,Hugues Richard,Louise Pilote BMJ 2005;330:1370
Adjusted hazard ratios (95%confidence intervals)
for death and recurrent congestive heart failure,
combined and alone, according to exposure group
Marie Hudson,Hugues Richard,Louise Pilote BMJ 2005;330:1370
Marie Hudson,Hugues Richard,Louise Pilote BMJ 2005;330:1370